A multidimensional meta-analysis of pharmacotherapy for bulimia nervosa: Summarizing the range of outcomes in controlled clinical trials

Harvard Review of Psychiatry

Volumn 10, Issue 4, 2002, Pages 193-211

  Nakash Eisikovits, Ora ^a   Dierberger, Amy ^a   Westen, Drew ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BROFAROMINE; DESIPRAMINE; FENFLURAMINE; FLUOXETINE; IMIPRAMINE; ISOCARBOXAZID; LITHIUM; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

BEHAVIOR THERAPY; BULIMIA; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE THERAPY; DRUG EFFICACY; DRUG UTILIZATION; HUMAN; PRIORITY JOURNAL; REMISSION; REVIEW; STANDARDIZATION; TREATMENT OUTCOME;

EID: 0036077075     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.1080/10673220216226     Document Type: Review

References (98)

1. The efficacy and role of antidepressants in the treatment of bulimia nervosa
2. The use of selective serotonin reuptake inhibitors in eating disorders
3. The pharmacological management of bulimia nervosa: A critical review
4. Antidepressant drug therapy for bulimia: Current status
5. Antidepressants and bulimia: Where are we?
6. Pharmacological treatment
7. Medications in the treatment of eating disorders
8. Antidepressant medication in the treatment of bulimia nervosa
9. Pharmacotherapy of bulimia nervosa and binge eating disorder: Longer-term outcomes
10. Antidepressants versus psychotherapy for bulimia nervosa: A systematic review
11. Drug and group treatments for bulimia/bulimia nervosa
12. The psychopharmacotherapy of eating disorders
13. Bulimia nervosa: A meta-analysis of psychosocial and pharmacological treatments
14. Practice guideline for eating disorders
15. Drug treatment for bulimia nervosa
16. A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: An empirical examination of the status of empirically supported therapies
17. Writing meta-analytic reviews
18. Methods for defining and determining the clinical significance of treatment effects: Description, application, and alternatives
19. Clinical significance: A statistical approach to defining meaningful change in psychotherapy research
20. Normative comparisons for the evaluation of clinical significance
21. Normative data for normative comparisons
22. Therapy outcome research methods
23. Recovery and relapse in anorexia and bulimia nervosa: A 7.5-year follow-up study
24. Outcome in bulimia nervosa
25. Cluster B personality disorder characteristics predict outcome in the treatment of bulimia nervosa
26. Changes in self-reported food intake in bulimics as a consequence of antidepressant treatment
27. Suppression of bulimic symptoms with methylamphetamine
28. Treatment of bulimia with lithium
29. A meta-analysis of antidepressant outcome under "blinder" conditions
30. Blind man's bluff: Effectiveness and significance of psychotherapy and pharmacotherapy blinding procedures in a clinical trial
31. The Eating Attitudes Test: Psychometric features and clinical correlates
32. One-year follow-up of psychosocial and pharmocologic treatments for bulimia nervosa
33. Long-term outcome of antidepressant treatment for bulimia nervosa
34. Maintenance treatment and 6-month outcome for bulimic patients who respond to initial treatment
35. A trial of isocarboxazid in the treatment of bulimia nervosa
36. Treatment of bulimia with fenfluramine and desipramine
37. Bulimia: Independence of antibulimic and antidepressant properties of desipramine
38. Differences in treatment outcome between borderline and nonborderline bulimics at one-year follow-up
39. The selectivity of inclusion and exclusion criteria in bulimia nervosa treatment studies
40. Metaanalysis of treatment studies for bulimia
41. Establishing guidelines for pharmacotherapy trials in bulimia nervosa and anorexia nervosa
42. Value of flow diagrams in reports of randomized controlled trials
43. Imipramine in the treatment of bulimia: A double-blind controlled study
44. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: A controlled comparison
45. Intensive nutritional counselling in bulimia nervosa: A role for supplementation with fluoxetine?
46. A placebo-controlled trial of d-fenfluramine in bulimia nervosa
47. Fluoxetine versus placebo: A double-blind study with bulimic inpatients undergoing intensive psychotherapy
48. Fluoxetine in the treatment of bulimia nervosa: A multicenter, placebo-controlled, double-blind trial
49. A randomized controlled trial of fluoxetine and cognitive behavioral therapy for bulimia nervosa: Short-term outcome
50. Long-term fluoxetine treatment of bulimia nervosa
51. Treatment of bulimia with bupropion: A multicenter controlled trial
52. Treatment of bulimia nervosa with lithium carbonate: A controlled study
53. Treating bulimia nervosa with desipramine: A double blind, placebo controlled study
54. Fluoxetine in the treatment of anxiety, depressive symptoms, and eating-related symptoms in bulimia nervosa
55. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine
56. A placebo-controlled, double-blind trial of amitriptyline in bulimia
57. A comparison study of antidepressants and structured intensive group psychotherapy in the treatment of bulimia nervosa
58. Bulimia treated with imipramine: A placebo-controlled, double-blind study
59. A placebo-controlled study of trazodone in bulimia nervosa
60. Phenelzine vs placebo in 50 patients with bulimia
61. A double-blind trial of phenelzine in bulimia
62. Medication and psychotherapy in the treatment of bulimia nervosa
63. Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects
64. Open trial of fluvoxamine in the treatment of bulimia nervosa
65. Treatment of bulimia with desipramine: A double-blind crossover study
66. Predictors of short-term treatment outcome in bulimia nervosa inpatients
67. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in bulimia nervosa
68. Antidepressant treatment of bulimia: The relationship between bingeing and depressive symptomatology
69. Ten-year follow-up of 50 patients with bulimia nervosa
70. Nomifensine treatment of bulimia: Results of an open trial
71. Outcome and clinical course in inpatient bulimic women: A 2- to 9-year follow-up study
72. Long-term use of fluoxetine in bulimia nervosa: A retrospective study
73. Fluvoxamine in prevention of relapse in bulimia nervosa: Effects on eating-specific psychopathology
74. Ipsapirone in the treatment of bulimia nervosa: An open pilot study
75. Antidepressant treatment of bulimia
76. Treatment of bulimia with antidepressants: Theoretical considerations and clinical findings
77. Vasotocin effects in depressive patients with eating disorders
78. Treatment of antidepressant-resistant bulimia with naltrexone
79. The use of opiate antagonists in treating bulimia: A study of low-dose versus high-dose naltrexone
80. Carbamazepine in the treatment of bulimia
81. Long-term outcome of bulimia nervosa
82. Use of L-tryptophan in treating bulimia
83. Comparison of cognitive-behavior therapy and desipramine in the treatment of bulimia nervosa
84. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa
85. Successful treatment of nonpurging bulimia nervosa with desipramine: A double-blind, placebo-controlled study
86. A follow-up study of patients with bulimia
87. A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia
88. Suppression of eating by fenfluramine in patients with bulimia nervosa
89. A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives
90. Bulimia nervosa: A placebo controlled double-blind therapeutic trial of mianserin
91. An open trial of MAO inhibitors in bulimia
92. Drugs in the treatment of bulimia nervosa
93. Treatment of bulimia with monoamine oxidase inhibitors
94. Treatment of bulimia with phenelzine: A double-blind placebo-controlled study
95. Trazodone in the treatment of bulimia